ALK and anaplastic large cell lymphoma: This independent system demonstrates resistance in ALK+ ALCL lines is driven at least in part by acquired ALK kinase-domain mutations, and confirms previous observations that mutations arising in response to one drug may affect multiple inhibitors of the same target.